<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name><publisher-loc>US</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5631192</article-id><article-id pub-id-type="doi">10.1093/ofid/ofx163.1158</article-id><article-id pub-id-type="publisher-id">ofx163.1158</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstract</subject></subj-group></subj-group></article-categories><title-group><article-title>Transcriptome Analysis in Human Breast Milk and Blood after Inactivated or Attenuated Influenza Immunization</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Schlaudecker</surname><given-names>Elizabeth P</given-names></name><degrees>MD, MPH</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Goll</surname><given-names>Johannes</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Jensen</surname><given-names>Travis</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Petrie</surname><given-names>Carey</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Gelber</surname><given-names>Casey</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="AF0002">2</xref></contrib><contrib contrib-type="author"><name><surname>Dexheimer</surname><given-names>Phillip</given-names></name><degrees>MS</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib><contrib contrib-type="author"><name><surname>Steinhoff</surname><given-names>Mark</given-names></name><degrees>MD, FIDSA</degrees><xref ref-type="aff" rid="AF0001">1</xref></contrib><contrib contrib-type="author"><name><surname>Bernstein</surname><given-names>David I</given-names></name><degrees>MD, MA, FIDSA</degrees><xref ref-type="aff" rid="AF0003">3</xref></contrib></contrib-group><aff id="AF0001">
<label>1</label>
<institution>Division of Infectious Diseases, Global Health Center, Cincinnati Children&#x02019;s Hospital Medical Center</institution>, <addr-line>Cincinnati, Ohio</addr-line></aff><aff id="AF0002">
<label>2</label>
<institution>The EMMES Corporation</institution>, <addr-line>Rockville, Maryland</addr-line></aff><aff id="AF0003">
<label>3</label>
<institution>Cincinnati Children&#x02019;s Hospital Medical Center</institution>, <addr-line>Cincinnati, Ohio</addr-line></aff><author-notes><fn id="fn-0001"><p>
<bold>Session:</bold> 161. Influenza and Influenza Vaccines</p><p>
<italic>Friday, October 6, 2017: 12:30 PM</italic>
</p></fn></author-notes><pub-date pub-type="collection"><season>Fall</season><year>2017</year></pub-date><pub-date pub-type="epub" iso-8601-date="2017-10-04"><day>04</day><month>10</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>04</day><month>10</month><year>2017</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. --><volume>4</volume><issue>Suppl 1</issue><issue-title>ID Week 2017 Abstracts</issue-title><fpage>S454</fpage><lpage>S455</lpage><permissions><copyright-statement>&#x000a9; The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America.</copyright-statement><copyright-year>2017</copyright-year><license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p></license></permissions><self-uri xlink:href="ofx163.1158.pdf"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>The goal of this study was to identify transcriptomic signatures (RNA-Seq) in human peripheral blood mononuclear cells (PBMCs) and breast milk lymphocyte cells (BMLCs) in response to trivalent inactivated influenza vaccine (TIV) or live attenuated influenza vaccine (LAIV).</p></sec><sec id="s2"><title>Methods</title><p>We performed a randomized, double-blind study in breastfeeding women who received either LAIV and intramuscular placebo, or TIV and intranasal placebo. A subset of subjects with available samples (LAIV, <italic>n =</italic> 10 and TIV, <italic>n =</italic> 6) was used for this study. Human milk was collected on days 0, 2, 8, and 28, and blood samples were collected on days 0 and 28. PBMC and BMLC RNA was extracted for RNA-Seq and differentially expressed (DE) gene analysis.</p></sec><sec id="s3"><title>Results</title><p>We identified a total of 382 DE BMLC genes in the LAIV group, most of which were up-regulated at day 28. DE genes were preferentially involved in innate immune signaling pathways including cytokine-cytokine receptor interaction, TNF signaling, and NF-kappa B signaling. For TIV, 3 DE genes were identified of which 2 (<italic>IL1A</italic> and <italic>IL1B</italic>) overlapped with LAIV. Response time trends for co-expressed gene clusters by vaccine group showed that LAIV generally induced an early (day 2) up-regulation of innate immune signaling pathway genes, while TIV induced peak innate immune signaling gene responses ahead of LAIV (day 8 vs. day 28). A group of known interferon-alpha/&#x003b2;-inducible genes (<italic>IFIT3</italic>, <italic>OAS3</italic>, <italic>IFI44L</italic>, <italic>MX1</italic>, <italic>OAS2</italic>, <italic>IFIT1</italic>, <italic>IFI6</italic>) showed higher responses at day 2 for TIV but stronger peak levels by day 28 for the LAIV group (Fig 1). While no such innate immune signaling responses were observed in PBMCs at day 28, we identified an up-regulation of IgG gene <italic>(IGHG1</italic> and <italic>IGHG3</italic>) expression in the TIV group (Fig 2).</p></sec><sec id="s4"><title>Conclusion</title><p>We observed increased innate immune signaling responses in BMLC but not in PBMC at day 28 for the LAIV group. We hypothesize that breastfeeding extends the innate response to LAIV via mucosal immunity. Gene cluster time trends indicated an earlier innate immune signaling response for TIV. The day 28 increase in <italic>IGHG3</italic> gene expression levels in TIV group PBMCs was correlated with corresponding increases in serum ELISA IgG titers for the influenza B antigen (Fig 3). Additional studies are required to investigate the differences in innate response signaling seen for BMLC and PBMC in this study.</p><fig fig-type="figure" id="F1" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0503"/></fig><fig fig-type="figure" id="F2" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0504"/></fig><fig fig-type="figure" id="F3" orientation="portrait" position="float"><graphic xlink:href="OFIDIS_ofx163_IF0505"/></fig></sec><sec id="s5"><title>Disclosures</title><p>
<bold>All authors:</bold> No reported disclosures.</p></sec></abstract><counts><page-count count="2"/></counts></article-meta></front></article>